Young startups backed by nanoparticle tech face a world hurdles before reaching the clinic. It’s been decades since the first innovations with nanotechnology – and experts are asking, “Where are all the drugs?” It’s been more than 20 years since the FDA approved the first nanoparticle drug, Doxil. At the time, nanoparticles were heralded as a […]
Cerulean reviews clinical assets, nanoparticle-drug conjugates
Cerulean Pharma Inc. (NSDQ:CERU) said today that its board of directors launched a strategic review of its assests, considering alternatives for its clinical assets and nanoparticle-drug conjugate platform. Waltham, Mass.-based Cerulean said it could consider a sale, a merger, or an investment into the company. The board is also floating the possibility of a sale or […]
Cerulean promotes Eliasof to senior VP & CSO | Personnel Moves, Oct. 26, 2016
Cerulean promotes Eliasof to senior VP & CSO Cerulean Pharma (NSDQ:CERU) said today that it named Scott Eliasof as senior VP and CSO, promoting him from VP of research. He joined the Waltham, Mass.-based company in 2007. Before coming on board to Cerulean, Eliasof was the director of the chemical biology platform at the Broad […]
Cerulean, Novartis ink $5m deal to co-develop nanoparticle-drug conjugates
UPDATED Oct. 20, 2016, with Cerulean share price movement. Cerulean Pharma Inc. (NSDQ:CERU) said today that it inked a deal with Novartis (NYSE:NVS) to develop nanoparticle-drug conjugates. The products will match Cerulean’s tumor-targeting tech with Novartis compounds directed at up to 5 targets. The agreement calls for Cerulean to receive $5 million plus funding for 5 full-time equivalents […]
